Last reviewed · How we verify
NCT04893070: COVIDAMBUCMA1
Impact of SARS-CoV-2 (COVID-19) Infection, Treated in Ambulatory Care, on Long-term Quality of Life in a Parisian Military Population
trial testing Questionnaires COVID+ in SARS-CoV2 Infection in 173 participants. Completed in 4 July 2022.
4 July 2022
Quick facts
| Lead sponsor | Direction Centrale du Service de Santé des Armées |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 173 |
| Start date | 15 July 2021 |
| Primary completion | 4 July 2022 |
| Estimated completion | 4 July 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Questionnaires COVID+
- Questionnaires COVID-
Conditions studied
- SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →
- Covid19 — all drugs for Covid19 →
Sponsor
Direction Centrale du Service de Santé des Armées — full company profile →
Who can join
18 and older, any sex, with SARS-CoV2 Infection or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In April 2020, a meta-analysis on the long-term sequelae of respiratory syndromes related to seasonal coronaviruses (SARS and MERS) showed a significant alteration in quality of life, with in particular a decrease in physical and emotional capacities and a deterioration of social life. An improvement of the quality of life is evidenced after 6 months but without reaching the level usually observed in healthy people. The impact of SARS-CoV-2 infection on quality of life can be explained by the persistence of pleomorphic symptoms in the medium to long term. In the military population, the majority of SARS-CoV-2 cases present minor to moderate forms of the disease. Military personnel have living conditions that differ from those of the general population, in particular because of their geographic mobility, which may be responsible for isolation from the family. This isolation can be regular (we speak of "geographical celibacy" when the soldier is posted in a geographical area far from the family unit) and/or occasional, during missions on the national territory or outside. This singularity justifies a study on the impact of SARS-CoV-2 (COVID-19) infection on the quality of life in this specific population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04893070
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV2 Infection
Currently open trials in the same condition.
- NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
- NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting
Other Direction Centrale du Service de Santé des Armées trials
Trials by the same sponsor.
- NCT07352904 — Exploration Strategies in Night Vision Sensors · not yet recruiting
- NCT07344493 — Average ANKLE GO Score in the Objective Functional Assessment of the Ankle in Healthy Military Personnel (ANKMIL) · completed
- NCT06996275 — Attachment and Post-Traumatic Stress Disorder in Military Personnel: Characterization of the French Military Population, · not yet recruiting
- NCT06490029 — Diagnostic of Various Ototoxicity Induced by Cancer Treatment · recruiting
- NCT06174181 — Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degenerat · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04893070 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Direction Centrale du Service de Santé des Armées
- Last refreshed: 17 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04893070.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing